MindMaze Therapeutics Shareholders Reject Capital Increase, Elect New Board Members at Annual General Meeting

MindMaze Therapeutics Holding SA (SIX: MMTX), a global leader in scalable precision neurotherapeutics, announced the results of its Annual General Meeting held on June 25, 2026. Shareholders approved all proposals submitted by the Board of Directors, except the proposed increase in conditional share capital, which failed to obtain the required qualified majority.

The rejection of the capital increase may impact the company’s future financing flexibility. However, the approval of other key items, including the 2025 annual report and financial statements, indicates continued shareholder confidence in the company’s strategic direction.

Shareholders re-elected Walid Hanna, Olaf Blanke, and Martin Reiss to the Board of Directors. Additionally, Brad Hollinger, Founder, Chairman and Chief Executive Officer of Vibra Healthcare, and Zach Henderson, Chief Executive Officer of MindMaze Therapeutics, were elected as new members. Hollinger brings extensive healthcare leadership experience, while Henderson’s insider perspective as CEO could align board decisions with operational realities.

Shareholders also approved the appropriation of available earnings, discharge of board members and executive committee, re-election of Walid Hanna as Chairman, elections to the Nomination and Compensation Committee, re-election of the Independent Proxy and statutory auditor, compensation proposals, and the consultative vote on the 2025 Compensation Report.

The company highlighted that further details on proposals were available in the AGM Invitation. Detailed voting results will be published on the company’s website later today.

MindMaze Therapeutics focuses on scalable precision neurotherapeutics, integrating advanced software, sensors, and AI-driven analytics to provide a continuum of care for neurological disorders like stroke and Parkinson’s disease. Their FDA-cleared and CE-marked products aim to address clinician shortages through reimbursable solutions. More information is available at www.mindmazetherapeutics.com.

The outcome of the AGM, especially the rejected capital increase, could influence the company’s ability to fund research and development or pursue acquisitions. The election of new board members may also signal a shift in strategic priorities as MindMaze continues to operationalize neurorestorative medicine.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is MindMaze Therapeutics Shareholders Reject Capital Increase, Elect New Board Members at Annual General Meeting.

The post MindMaze Therapeutics Shareholders Reject Capital Increase, Elect New Board Members at Annual General Meeting appeared first on citybuzz.